A detailed history of C World Wide Group Holding A transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, C World Wide Group Holding A holds 71,557 shares of VRTX stock, worth $32.6 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares
71,557
Previous 71,557 -0.0%
Holding current value
$32.6 Million
Previous $29.9 Million 12.13%
% of portfolio
0.36%
Previous 0.34%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

SELL
$343.0 - $410.68 $7.55 Million - $9.03 Million
-22,000 Reduced 23.52%
71,557 $29.1 Million
Q3 2022

Nov 03, 2022

SELL
$273.83 - $305.53 $4.11 Million - $4.58 Million
-15,000 Reduced 13.82%
93,557 $27.1 Million
Q1 2021

May 04, 2021

BUY
$207.02 - $241.31 $4.14 Million - $4.83 Million
20,000 Added 22.58%
108,557 $23.3 Million
Q4 2020

Feb 05, 2021

BUY
$207.01 - $276.09 $4.14 Million - $5.52 Million
20,000 Added 29.17%
88,557 $20.9 Million
Q1 2019

May 03, 2019

SELL
$163.73 - $194.7 $782,629 - $930,666
-4,780 Reduced 6.52%
68,557 $12.6 Million
Q4 2018

Feb 12, 2019

SELL
$151.91 - $192.21 $304,731 - $385,573
-2,006 Reduced 2.66%
73,337 $12.2 Million
Q3 2018

Nov 05, 2018

BUY
$167.73 - $192.74 $1.81 Million - $2.08 Million
10,813 Added 16.76%
75,343 $14.5 Million
Q2 2018

Aug 03, 2018

BUY
$145.72 - $169.96 $2.35 Million - $2.74 Million
16,134 Added 33.34%
64,530 $11 Million
Q1 2018

May 03, 2018

SELL
$151.6 - $177.13 $29,107 - $34,008
-192 Reduced 0.4%
48,396 $7.89 Million
Q4 2017

Feb 07, 2018

BUY
$137.28 - $155.55 $1.43 Million - $1.62 Million
10,442 Added 27.37%
48,588 $7.28 Million
Q3 2017

Nov 06, 2017

BUY
$148.13 - $162.24 $5.65 Million - $6.19 Million
38,146
38,146 $5.8 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $117B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track C World Wide Group Holding A Portfolio

Follow C World Wide Group Holding A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of C World Wide Group Holding A, based on Form 13F filings with the SEC.

News

Stay updated on C World Wide Group Holding A with notifications on news.